Angiotensin II receptor blockers decreased blood glucose levels: A longitudinal survey using data from electronic medical records

Cardiovascular Diabetology

Volumn 6, Issue , 2007, Pages

  Kitamura, Noboru ^a   Takahashi, Yasuo ^a   Yamadate, Shuukoh ^b   Asai, Satoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; GLUCOSE; HEMOGLOBIN A1C; LOSARTAN POTASSIUM; NU LOTAN; OLMESARTAN; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD ANALYSIS; CORRELATION ANALYSIS; COVARIANCE; DIABETES MELLITUS; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; JAPAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL RECORD REVIEW; MONOTHERAPY; SEX DIFFERENCE; TREATMENT DURATION; BLOOD; DIABETIC ANGIOPATHY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RETROSPECTIVE STUDIES;

EID: 36649033813     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-6-26     Document Type: Article

References (19)

1. Folli F Kahn CR Hansen H Bouchie JL Feener EP: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997, 100(9):2158-2169. 508410 9410892
2. Folli F Saad MJ Velloso L Hansen H Carandente O Feener EP Kahn CR: Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999, 107(2):133-139. 10320054
3. Fujimoto M Masuzaki H Tanaka T Yasue S Tomita T Okazawa K Fujikura J Chusho H Ebihara K Hayashi T: An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 2004, 576(3):492-497. 10.1016/ j.febslet.2004.09.027 15498586
4. Furuhashi M Ura N Higashiura K Murakami H Tanaka M Moniwa N Yoshida D Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42(1):76-81. 10.1161/01.HYP.0000078490.59735.6E 12796280
5. Haenni A Lithell H: Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994, 43(4):455-461. 10.1016/0026-0495(94)90076-0 8159103
6. Kaplan NM: Effects of antihypertensive therapy on insulin resistance. Hypertension 1992, 19(1 Suppl): I116-118. 1346122
7. Kuzuya T Nakagawa S Satoh J Kanazawa Y Iwamoto Y Kobayashi M Nanjo K Sasaki A Seino Y Ito C: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002, 55(1):65-85. 10.1016/S0168-8227(01)00365-5 11755481
8. Fitzmaurice GM Laird NM Ware JH: Applied longitudinal analysis. New York: John Wiley & Sons, Inc 2004.
9. Landsberg L: Insulin sensitivity in the pathogenesis of hypertension and hypertensive complications. Clin Exp Hypertens 1996, 18(3-4):337-346. 8743025
10. Landsberg L: Insulin-mediated sympatRetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 2001, 19(3 Pt 2):523-528. 10.1097/ 00004872-200103001-00001 11327624
11. Lithell H Pollare T Vessby B: Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1992, 1(2):92-101. 1366265
12. Okada K Hirano T Ran J Adachi M: Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 2004, 27(4):293-299. 10.1291/hypres.27.293 15127887
13. Paolisso G Gambardella A Verza M D'Amore A Sgambato S Varricchio M: ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992, 6(3):175-179. 1629885
14. Ran J Hirano T Fukui T Saito K Kageyama H Okada K Adachi M: Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: An implication for hypertension-related insulin resistance. Metabolism 2006, 55(4):478-488. 10.1016/j.metabol.2005.10.009 16546478
15. Scheen AJ: Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004, 30(6):498-505. 10.1016/S1262-3636(07)70147-7 15671919
16. Scheen AJ: Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004, 64(22):2537-2565. 10.2165/ 00003495-200464220-00004 15516153
17. Scheen AJ: Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004, 30(6):487-496. 10.1016/S1262-3636(07)70146-5 15671918
18. Schupp M Clemenz M Gineste R Witt H Janke J Helleboid S Hennuyer N Ruiz P Unger T Staels B: Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005, 54(12):3442-3452. 10.2337/diabetes.54.12.3442 16306360
19. Weir MR Dzau VJ: The renin-angiotensAn-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999, 12(12 Pt 3):205S-213S. 10.1016/S0895-7061(99)00103-X 10619573